HLN Haleon plc
Company Analysis
Latest News
🔴 Haleon is trading 4.4% down in after-hours trading after Jefferies downgrades it to Hold
Haleon is trading at $8.85, down 4.38%, after Jefferies downgraded it to Hold from Buy on November 4. - Jefferies cut its target to 320p from 400p, citing...
🟢 Haleon is trading 4.1% up today amid U.S. risk-on trading after midterm results
Haleon is trading 4.1% up at $9.21, with no clear company-specific catalyst; the move coincides with broad risk-on trading after U.S. midterm results. -...
Haleon's Guidance Cut Erases Months of Gains — Can a Buyback Cushion a Business That Depends on People Getting Sick?
Shares of Haleon plc cratered as much as 15% on October 29 after the maker of Sensodyne, Advil, and Panadol slashed its full-year sales outlook, raising a...
🟢 Haleon is trading 4.62% up in after-hours trading; with no clear catalyst identified
Haleon is trading at $9.05, up 4.62% after hours, with no clear catalyst identified. - This compares with the supplied October 30 regular-session close of...
🔴 Haleon is trading 13.25% down after cutting 2026 growth outlook to around 2.5%
Haleon is trading 13.25% down at $8.68 after lowering its 2026 organic revenue growth outlook to around 2.5%, from 3%–5%. - Its October 29 update reported...
🔴 Haleon is trading 12% down in pre-market after lowering 2026 growth guidance to around 2.5%
Haleon is trading 12.1% down at $8.79 in pre-market after cutting its 2026 organic revenue growth guidance to around 2.5%. - The October 29 Q3 update reported...
Haleon plc Q3 2026 Earnings Preview: What Analysts Expect on October 29, 2026
Haleon plc is anticipated to report Q3 2026 revenue of £2.93 billion and adjusted diluted EPS of £0.057, with the stock currently trading at £3.82 compared to...
Haleon targets weight-loss drug users, driving 24% sales lift
Haleon is targeting U.S. consumers using GLP-1 weight-loss medications such as Wegovy and Zepbound. The maker of Advil and TUMS is partnering with retailers...
🔴 Haleon is trading 4.2% down today amid healthcare-sector weakness
Haleon is trading 4.2% down at $9.20 amid broad healthcare-sector weakness and softer overall market sentiment on September 8, 2026. - No fresh negative...
Haleon launches $2 billion debt buyback, optimizing its balance sheet
Haleon subsidiary Haleon US Capital LLC launched a cash tender offer for $1,999,350,000 of its outstanding debt. The offer targets 3.375% Fixed Rate Senior...
Haleon plc Q2 2026 Earnings Preview: What Analysts Expect on July 30, 2026
Haleon plc is expected to report Q2 2026 revenue of $3.81 billion and EPS of $0.14, with the current stock price of $11.15 trading below the average analyst...
Haleon plc Q1 2026 Earnings Preview: What Analysts Expect on April 29, 2026
Haleon is expected to report Q1 2026 revenue of approximately $3.80 billion and an EPS of $0.25, with the current stock price of $9.56 trading well below the...